ReviewHuman vaccines & immunotherapeutics2024
4CMenB journey to the 10-year anniversary and beyond.
Review in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.Human vaccines & immunotherapeutics · 2026Trial
- Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Preclinical Evaluation of Novel ConservedVaccines · 2026Article
- Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the Netherlands.Infectious diseases and therapy · 2026Article
- A Multidesign Study of 4CMenB Vaccine Effectiveness and Impact on Meningococcal Carriage and Gonorrhea in Northern Territory Adolescents and Young People.Open forum infectious diseases · 2026Article
- Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis.NPJ vaccines · 2026Article
- Defining the Efficacy of Meningococcal B Vaccines Against Gonococcal Acquisition: The Current Landscape.Journal of the International AIDS Society · 2026Review
- [Use of vaccines to prevent the development of bacterial resistance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Outer membrane vesicles: Versatile nanocarriers for therapeutic delivery and immune modulation.Acta pharmaceutica Sinica. B · 2026Review
- Perspective on the pathogenic Neisseria: milestones, challenges, and future directions.NPJ vaccines · 2026Review
- Recent advancements in pediatric purulent meningitis: diagnosis and treatment.Italian journal of pediatrics · 2026Review
- The relationship between socio-economic inequity indicators and 4CMenB vaccination rates in infants and adolescents in Spain: An ecological correlation study.Human vaccines & immunotherapeutics · 2025Article
- Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Observational
- Correlates of Meningococcal B Vaccination and Health Behavior Profiles Among MSM in China.Vaccines · 2025Article
- Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas.Vaccines · 2025Review
- Article
- Meningococcal vaccine 4CMenB elicits a robust cellular immune response that targets but is not consistently protective againstmSphere · 2025Article
- Beta-Lactam Antibiotics Promote Extracellular Vesicle Production of Staphylococcus aureus Through ROS-Mediated Lipid Metabolic Reprogramming.Journal of extracellular vesicles · 2025Article
- Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccine.mSphere · 2025Review
- Use of 4CMenB vaccine in the control of an outbreak of serogroup B invasive meningococcal disease in an elderly care home, England, November 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 countries worldwide. Real-world evidence (RWE) from the last decade confirms its effectiveness and impact, with infant immunization programs showing vaccine effectiveness of 71-95% against invasive MenB disease and cross-protection against non-B serogroups, including a 69% decrease in serogroup W cases in 4CMenB-eligible cohorts in England. RWE from different countries also demonstrates the potential for additional moderate protection against gonorrhea in adolescents. The real-world safety profile of 4CMenB is consistent with prelicensure reports. Use of the endogenous complement human serum bactericidal antibody (enc-hSBA) assay against 110 MenB strains may enable assessment of the immunological effectiveness of multicomponent MenB vaccines in clinical trial settings. Equitable access to 4CMenB vaccination is required to better protect all age groups, including older adults, and vulnerable groups through comprehensive immunization policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.